Loading clinical trials...
Loading clinical trials...
TheraBionic P1 Device for Patients With Advanced Hepatocellular Carcinoma (HCC) Who Fail First and Second Line Therapy
Conditions
Interventions
TheraBionic P1
Locations
6
United States
Karmanos Cancer Institute at McLaren Bay Region
Bay City, Michigan, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
Karmanos Cancer Institute at McLaren Flint
Flint, Michigan, United States
Karmanos Cancer Institute at McLaren Greater Lansing
Lansing, Michigan, United States
Karmanos Cancer Institute at McLaren Lapeer Region
Lapeer, Michigan, United States
Karmanos Cancer Institute at McLaren Central Michigan, Morey Cancer Center
Mount Pleasant, Michigan, United States
Start Date
October 20, 2025
Primary Completion Date
August 31, 2028
Completion Date
August 31, 2028
Last Updated
April 13, 2026
NCT05990959
NCT05277675
NCT02423343
NCT01009593
Lead Sponsor
Barbara Ann Karmanos Cancer Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions